-
Je něco špatně v tomto záznamu ?
Novel platinum(II) and palladium(II) complexes with cyclin-dependent kinase inhibitors: synthesis, characterization and antitumour activity
Szucová L, Trávnícek Z, Zatloukal M, Popa I.
Jazyk angličtina Země Velká Británie
- MeSH
- cyklin-dependentní kinasy antagonisté a inhibitory MeSH
- diferenciální skenovací kalorimetrie MeSH
- financování organizované MeSH
- hmotnostní spektrometrie s elektrosprejovou ionizací MeSH
- inhibitory enzymů farmakologie chemie MeSH
- krystalografie rentgenová MeSH
- magnetická rezonanční spektroskopie MeSH
- molekulární modely MeSH
- palladium farmakologie chemie MeSH
- protinádorové látky farmakologie chemie MeSH
- sloučeniny platiny farmakologie chemická syntéza chemie MeSH
- spektrofotometrie infračervená MeSH
The Pt(II) and Pd(II) complexes of the types cis-[Pt(L(1))(2)Cl(2)].H(2)O (1), cis-[Pt(L(2))(2)Cl(2)].3H(2)O (2), trans-[Pd(L(1))(2)Cl(2)].H(2)O (3), trans-[Pd(L(2))(2)Cl(2)].H(2)O (4), trans-[Pd(L(3))(2)Cl(2)].2DMF (5) and trans-[Pd(L(4))(2)Cl(2)].2DMF (6) (L(1)-L(4)=cyclin-dependent kinase inhibitors derived from 6-benzylamino-9-isopropylpurine) have been prepared and characterized. The complexes have been studied by elemental analyses, conductivity measurements, ES+ MS, FT-IR, (1)H, (13)C and (195)Pt NMR spectra, differential scanning calorimetry and thermogravimetric analysis. The molecular structures of L(1), trans-[Pd(L(3))(2)Cl(2)].2DMF (5) and trans-[Pd(L(4))(2)Cl(2)].2DMF (6) have been determined by single crystal X-ray analysis. The complexes have been tested in vitro due to their presumable anticancer activity against the following human cancer cell lines: K-562, MCF7, G-361 and HOS. Satisfying results were obtained for the complex 1 with IC(50) values of 6 microM acquired against G-361 as well as against HOS cell lines. The lowest values of IC(50) were achieved for the complexes 3 and 4 against MCF 7 cell line with IC(50) 3 microM(for 3) and also 3 microM (for 4).
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07519340
- 003
- CZ-PrNML
- 005
- 20111210130749.0
- 008
- 090313s2006 xxk e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Plíhalová, Lucie $7 xx0110494
- 245 10
- $a Novel platinum(II) and palladium(II) complexes with cyclin-dependent kinase inhibitors: synthesis, characterization and antitumour activity / $c Szucová L, Trávnícek Z, Zatloukal M, Popa I.
- 314 __
- $a Department of Inorganic Chemistry, Palacký University, Krízkovského 10, CZ-771 47 Olomouc, Czech Republic
- 520 9_
- $a The Pt(II) and Pd(II) complexes of the types cis-[Pt(L(1))(2)Cl(2)].H(2)O (1), cis-[Pt(L(2))(2)Cl(2)].3H(2)O (2), trans-[Pd(L(1))(2)Cl(2)].H(2)O (3), trans-[Pd(L(2))(2)Cl(2)].H(2)O (4), trans-[Pd(L(3))(2)Cl(2)].2DMF (5) and trans-[Pd(L(4))(2)Cl(2)].2DMF (6) (L(1)-L(4)=cyclin-dependent kinase inhibitors derived from 6-benzylamino-9-isopropylpurine) have been prepared and characterized. The complexes have been studied by elemental analyses, conductivity measurements, ES+ MS, FT-IR, (1)H, (13)C and (195)Pt NMR spectra, differential scanning calorimetry and thermogravimetric analysis. The molecular structures of L(1), trans-[Pd(L(3))(2)Cl(2)].2DMF (5) and trans-[Pd(L(4))(2)Cl(2)].2DMF (6) have been determined by single crystal X-ray analysis. The complexes have been tested in vitro due to their presumable anticancer activity against the following human cancer cell lines: K-562, MCF7, G-361 and HOS. Satisfying results were obtained for the complex 1 with IC(50) values of 6 microM acquired against G-361 as well as against HOS cell lines. The lowest values of IC(50) were achieved for the complexes 3 and 4 against MCF 7 cell line with IC(50) 3 microM(for 3) and also 3 microM (for 4).
- 650 _2
- $a protinádorové látky $x farmakologie $x chemie $7 D000970
- 650 _2
- $a diferenciální skenovací kalorimetrie $7 D002152
- 650 _2
- $a krystalografie rentgenová $7 D018360
- 650 _2
- $a cyklin-dependentní kinasy $x antagonisté a inhibitory $7 D018844
- 650 _2
- $a inhibitory enzymů $x farmakologie $x chemie $7 D004791
- 650 _2
- $a magnetická rezonanční spektroskopie $7 D009682
- 650 _2
- $a molekulární modely $7 D008958
- 650 _2
- $a palladium $x farmakologie $x chemie $7 D010165
- 650 _2
- $a sloučeniny platiny $x farmakologie $x chemická syntéza $x chemie $7 D017671
- 650 _2
- $a hmotnostní spektrometrie s elektrosprejovou ionizací $7 D021241
- 650 _2
- $a spektrofotometrie infračervená $7 D013055
- 650 _2
- $a financování organizované $7 D005381
- 700 1_
- $a Zatloukal, Marek $7 xx0113001
- 700 1_
- $a Trávníček, Zdeněk, $d 1964- $7 ola2004209199
- 700 1_
- $a Popa, Igor $7 jo2012690165
- 773 0_
- $w MED00000769 $t Bioorganic & medicinal chemistry $g Roč. 14, č. 2 (2006), s. 479-491 $x 0968-0896
- 910 __
- $a ABA008 $b x $y 9
- 990 __
- $a 20090312170439 $b ABA008
- 991 __
- $a 20110929095534 $b ABA008
- 999 __
- $a ok $b bmc $g 637149 $s 489925
- BAS __
- $a 3
- BMC __
- $a 2006 $b 14 $c 2 $d 479-491 $i 0968-0896 $m Bioorganic & medicinal chemistry $x MED00000769
- LZP __
- $a 2009-B1/vtme
